US20454B1044
US20454B1044
Compass Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | 850.000 | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 72.839.000 | 57.475.000 | 26.7% | |
| Operating Income | -72.839.000 | -56.625.000 | 28.6% |
| Pretax Income | -66.489.000 | -49.375.000 | 34.7% |
| Net Income Common Stockholders | -66.489.000 | -49.375.000 | 34.7% |
| -- | -- | -- | |
| -- | -- | -- |